Cancers,
Год журнала:
2024,
Номер
16(24), С. 4281 - 4281
Опубликована: Дек. 23, 2024
Background/Objectives:
Cardio-oncology
has
become
essential
in
addressing
cardiovascular
complications
from
cancer
therapies.
While
advancements
treatments
have
improved
survival
rates,
they
also
increase
risks.
This
study
evaluates
the
cardiotoxic
effects
of
cytostatic
treatments,
examining
relationship
between
tumor
characteristics,
such
as
histopathology
and
TNM
classification,
complications,
aiming
to
improve
cardiotoxicity
prevention
management
oncology
patients.
Methods:
We
conducted
a
retrospective
analysis
patients
treated
with
anthracyclines,
HER2-targeted
therapies,
radiotherapy.
Cardiac
function
was
monitored
via
echocardiography,
focusing
on
global
longitudinal
strain
left
ventricular
ejection
fraction
(LVEF).
troponins
natriuretic
peptides
were
measured
detect
subclinical
cardiotoxicity,
stratified
by
stage
histopathology.
Results:
Our
identified
significant
association
certain
anthracyclines
reduction
LVEF,
particularly
advanced-stage
cancer.
Biomarker
assessments
indicated
early
signs
before
clinical
symptoms
emerged.
The
findings
demonstrated
higher
prevalence
pre-existing
risk
factors.
Conclusions:
highlights
importance
personalized
treatment
protocols
minimizing
improving
quality
life
for
Regular
cardiac
monitoring,
combined
use
biomarkers,
can
help
identify
high-risk
early,
allowing
timely
interventions.
Future
research
should
focus
optimizing
cardioprotective
strategies
mitigate
risks
associated
modern
Clinical
Trial
Registration:
N/A
(retrospective
study).
Circulation Research,
Год журнала:
2025,
Номер
136(11), С. 1262 - 1285
Опубликована: Май 22, 2025
Heart
failure
(HF)
often
coexists
with
cancer.
Beyond
the
known
cardiotoxicity
of
some
cancer
treatments,
HF
itself
has
been
associated
increased
incidence.
The
2
conditions
share
common
risk
factors,
mechanisms,
and
interactions
that
can
worsen
patient
outcomes.
bidirectional
relationship
between
presents
a
complex
interplay
factors
are
not
fully
understood.
Recent
preclinical
evidence
suggests
may
promote
tumor
growth
via
release
protumorigenic
from
injured
heart,
revealing
as
potentially
condition.
Our
review
discusses
biological
crosstalk
cancer,
emphasizing
impact
on
growth,
inflammation,
modulating
immune
system
central
mechanisms.
We
further
explore
clinical
implications
this
connection
propose
future
research
directions.
Understanding
mechanistic
overlap
could
lead
to
new
biomarkers
therapies,
addressing
growing
prevalence
both
enhancing
approaches
diagnosis,
prevention,
treatment.
ABSTRACT
Purpose
This
study
explores
the
effects
of
anthracycline
chemotherapy
(AC)
on
breast
cancer
patients,
focusing
changes
in
body
composition,
advanced
echocardiographic
parameters
at
rest
and
during
exercise,
biomarkers;
subsequently
assesses
whether
these
are
associated
with
impaired
cardiorespiratory
fitness
(CRF).
Methods
In
this
prospective
study,
we
evaluated
women
early‐stage
undergoing
AC
three
visits:
before
AC,
1
month
after,
6
months
post‐AC.
Results
The
included
32
cancer,
functional
disability
increasing
from
9.0%
pre‐AC
to
43.8%
53.1%
At
month,
patients
exhibited
higher
rates
therapy‐related
cardiac
dysfunction
(CTRCD)
(85.7%
vs.
55.5%)
and,
showed
lower
left
ventricular
ejection
fraction
(LVEF),
reduced
contractile
reserve
stroke
volume
(SV);
along
elevated
IL‐6,
PlGF,
MPO
levels.
By
months,
maintained
CTRCD
(35.3%
0%),
SV
output
(CO),
global
longitudinal
strain
(GLS),
decreased
work
index
(GWI).
During
they
had
SV;
additionally,
levels
increased
visceral
fat.
our
multivariable
model:
age,
fat,
resting
GWI,
exercise
LVEF,
CO
were
independently
VO
2
peak.
Conclusion
Significant
persistent
CRF
reductions
common
While
LVEF
GLS
not
linked
peak,
MWI
were,
potentially
identifying
long‐term
heart
failure
risk
who
would
benefit
cardioprotective
strategies
like
cardio‐oncology
rehabilitation.
It
is
important
recognize
that
multifactorial,
as
demonstrated
by
age
fat
being
impact
non‐cardiac
factors
should
be
better
studied.
Our
findings
highlight
need
for
further
research
definition,
suggesting
CPET
echocardiography
could
enhance
stratification.
Medicina,
Год журнала:
2025,
Номер
61(2), С. 301 - 301
Опубликована: Фев. 10, 2025
Background
and
Objectives:
Cardio-oncology
addresses
the
growing
concern
of
cardiovascular
complications
arising
from
cancer
therapies.
Although
treatments
have
greatly
enhanced
survival
outcomes,
they
frequently
carry
substantial
risks
to
health.
This
research
examines
toxicity
associated
with
HER2-targeted
therapies,
focusing
on
interconnection
between
tumor
characteristics,
including
histopathological
profiles
TNM
classification,
development
complications.
The
objective
is
identify
key
correlations
that
inform
better
prevention
management
strategies
for
cardiotoxicity
in
oncology
patients.
Materials
Methods:
retrospective
study
analyzed
patients
undergoing
cytostatic
treatments,
particularly
anthracyclines,
radiotherapy,
Cardiac
function
was
monitored
using
echocardiographic
assessments,
global
longitudinal
strain
left
ventricular
ejection
fraction
(LVEF).
Patients
were
stratified
based
staging
findings
evaluate
treatment
regimens
outcomes.
Results:
analysis
revealed
a
significant
association
advanced
stages
reduced
LVEF,
stage
T4
showing
highest
prevalence
cardiac
dysfunction.
Cytostatic
such
as
anthracyclines
identified
contributors
cardiotoxicity,
advanced-stage
These
emphasize
importance
regular
monitoring
detect
early
signs
pre-existing
risk
factors
demonstrated
higher
Conclusions:
highlights
need
personalized
approaches
tailored
cardioprotective
improve
outcomes
enhance
quality
life
Future
studies
should
prioritize
developing
improved
reduce
linked
contemporary
treatments.
Breast Cancer Research and Treatment,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 2, 2025
Breast
cancer
treatment
results
in
increased
cardiotoxicity
risk;
a
risk-guided
approach
to
cardioprotection
has
not
been
fully
tested.
This
single-center,
randomized
Phase
I
trial
enrolled
patients
with
Stage
I-III
breast
who
planned
receive
anthracycline
and/or
trastuzumab
therapy.
An
internally
validated
risk
score
classified
participants
as
low
or
elevated
risk.
Elevated
were
open-label
carvedilol
usual
care
for
12
months,
beginning
at
therapy
initiation.
Study
visits
occurred
baseline,
3,
6,
9,
12,
and
24
months.
Primary
outcomes
included
feasibility,
safety,
tolerability.
Exploratory
echocardiography,
biologic,
patient-reported
measures.
Of
the
166
eligible
approached,
68
(41%)
agreed
participate
ultimately
enrolled.
Among
these
(median
age
52,
35%
Black),
49
19
Within
group,
13
6
care.
For
those
carvedilol,
median
maximum
dose
was
6.25
mg
twice
daily,
93%
adherence.
Adverse
events
of
interest
(grade
3
+
bradycardia,
hypotension,
fatigue)
9%
13%
care,
4%
groups.
One
(1.5%)
participant
experienced
cardiac
dysfunction.
There
no
substantial
differences
secondary
across
The
withdrawal
rate
7%.
1
demonstrates
that
strategy
can
be
applied
active
cancer.
However,
additional
strategies
are
necessary
optimize
design
execution
non-treatment
intervention
trials
NCT04023110.
Heart and Mind,
Год журнала:
2025,
Номер
9(2), С. 115 - 135
Опубликована: Март 1, 2025
Abstract
As
survival
rates
for
cancer
patients
improve
due
to
advancements
in
treatment
modalities,
there
is
an
increasing
prevalence
of
cardiovascular
complications,
necessitating
a
comprehensive
understanding
this
intersection.
This
review
aims
elucidate
the
intricate
relationship
between
and
disease,
highlighting
growing
concern
toxicity
associated
with
therapies.
It
explores
various
treatments,
including
chemotherapy,
targeted
therapies,
radiation,
their
risks,
such
as
heart
failure
ischemic
disease.
In
addition,
it
discusses
importance
proactive
risk
assessments
ongoing
monitoring
mitigate
adverse
outcomes.
Strategies
prevention
management,
lifestyle
modifications
pharmacologic
interventions,
are
also
examined
support
health
survivors.
Unlike
previous
reviews,
work
integrates
insights
from
multidisciplinary
collaborations,
emphasizing
underexplored
mechanisms
role
innovative
tools.
highlights
emerging
therapeutic
strategies
tailored
these
providing
forward-looking
perspective
critical
area
research.
The
need
collaborative
method
that
includes
oncologists,
cardiologists,
primary
care
providers
emphasized
ensure
integrated
addresses
both
health.
serves
resource
healthcare
professionals
seeking
long-term
outcomes
survivors
by
recognizing
managing
risks.
Journal of Clinical Medicine,
Год журнала:
2025,
Номер
14(9), С. 3083 - 3083
Опубликована: Апрель 29, 2025
Cardiovascular
diseases
and
cancer
are
the
two
primary
causes
of
mortality
worldwide.
Although
traditionally
regarded
as
distinct
pathologies,
they
share
numerous
pathophysiological
mechanisms
risk
factors,
including
chronic
inflammation,
insulin
resistance,
obesity,
metabolic
dysregulation.
Notably,
several
cancers
have
been
identified
closely
linked
to
cardiovascular
diseases,
lung,
breast,
prostate,
colorectal
cancers,
well
hematological
malignancies,
such
leukemia
lymphoma.
Additionally,
renal
pancreatic
exhibit
a
significant
association
with
complications,
partly
due
shared
factors
cardiotoxic
effects
therapies.
Addressing
overlapping
through
lifestyle
modifications-such
regular
physical
activity,
balanced
diet,
cessation
smoking
alcohol-has
proven
effective
in
reducing
both
CV
oncological
morbidity
mortality.
Furthermore,
even
patients
established
cancer,
structured
interventions
targeting
nutritional
optimization,
associated
improved
outcomes.
Beyond
modifications,
pharmacological
strategies
play
crucial
role
prevention
diseases.
Several
medications,
statins,
aspirin,
beta-blockers,
metformin,
pleiotropic
that
extend
beyond
their
indications,
demonstrating
potential
anti-neoplastic
properties
preclinical
observational
studies.
Recently,
novel
therapeutic
agents
garnered
attention
for
possible
cardioprotective
benefits.
Glucagon-like
peptide-1
receptor
agonists
(GLP-1
RAs)
sodium-glucose
cotransporter-2
inhibitors
(SGLT2is),
initially
developed
managing
type
2
diabetes,
shown
protective
effects,
alongside
emerging
evidence
modulating
cancer-related
pathways.
Inclisiran,
small
interfering
RNA
PCSK9,
effectively
lowers
LDL
cholesterol
may
contribute
risk,
implications
tumor
biology.
sacubitril/valsartan,
an
angiotensin
receptor-neprilysin
inhibitor,
has
revolutionized
heart
failure
management
by
improving
hemodynamic
parameters
exerting
anti-inflammatory
broader
disease
prevention.
Given
intricate
interplay
between
CVD
further
research
is
essential
clarify
exact
linking
these
conditions
assessing
therapies
This
review
aims
examine
consider
interventions,
emphasize
epidemiological
mechanistic
insights
into
intersection
health.
Pharmaceuticals,
Год журнала:
2025,
Номер
18(5), С. 681 - 681
Опубликована: Май 3, 2025
Cancer
remains
the
second
leading
cause
of
death
worldwide.
Doxorubicin
(DOX)
is
a
cornerstone
hematologic
malignancy
treatment,
but
it
limited
by
its
dose-dependent
cardiotoxicity,
to
systolic
and
diastolic
cardiac
dysfunction
and,
ultimately,
dilated
hypokinetic
cardiomyopathy.
Cardio-oncology
has
emerged
as
subspecialty
addressing
cardiovascular
complications
in
cancer
patients,
highlighting
preventive
therapeutic
strategies
reduce
therapy-related
(CTRCD).
Current
approaches,
including
beta-blockers,
renin–angiotensin
system
(RAS)
inhibitors,
statins,
offer
partial
cardioprotection.
Sodium-glucose
cotransporter-2
(SGLT2)
initially
developed
for
type
2
diabetes
mellitus
(T2DM),
demonstrate
pleiotropic
cardioprotective
effects
beyond
glycemic
control,
reduced
oxidative
stress,
inflammation,
myocardial
remodeling.
This
review
explores
interplay
between
anthracycline
therapy,
particularly
DOX,
cardiotoxicity
while
evaluating
SGLT2
inhibitors
novel
agents
cardio-oncology.
Preclinical
studies
suggest
attenuate
CTRCD
preserving
mitochondrial
function
inhibiting
apoptosis,
clinical
trials
highlight
their
efficacy
reducing
heart
failure
(HF)
hospitalizations
(CV)
mortality.
Integrating
into
cardio-oncology
protocols
could
revolutionize
management
CTRCD,
enhancing
patient
outcomes
oncology
care.
Considering
emerging
evidence,
may
provide
significant
benefits
patients
undergoing
those
with
elevated
risk
profiles.
We
recommend
that
future
prospective,
large-scale
further
evaluate
safety
these
therapy
optimize
individualized
treatment
strategies.